PMID- 35096257
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220201
IS  - 1941-2789 (Print)
IS  - 2689-9175 (Electronic)
IS  - 1941-2789 (Linking)
VI  - 14
IP  - 12
DP  - 2021 Dec
TI  - Assessing the Risk of Omalizumab Add-on Therapy for Chronic Idiopathic Urticaria 
      during the COVID-19 Pandemic.
PG  - 64-65
AB  - Amid the current COVID-19 pandemic, there is concern for increased risk of 
      infection while on immunomodulatory therapy. Omalizumab, a monoclonal antibody, 
      is an add-on therapy for the treatment of chronic idiopathic urticaria (CIU) when 
      first line therapy alone fails to achieve appropriate response. Current 
      understanding of the response to COVID-19 infection is largely varied and 
      actively under investigation. In the context of a pandemic, it is important to 
      consider the safety profile of omalizumab as it modulates the immune system. We 
      reviewed data from pivotal Phase III clinical trials investigating omalizumab use 
      in CIU patients with a focus on reported respiratory-related adverse events (AEs) 
      to assess these risks. Results from three phase III trials show that omalizumab 
      adjunct therapy does not significantly increase infection risk and severity.
CI  - Copyright (c) 2021. Matrix Medical Communications. All rights reserved.
FAU - Walia, Shikha
AU  - Walia S
AD  - Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, 
      Florida.
AD  - Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee.
AD  - Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona.
AD  - Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, 
      California.
FAU - Ivanic, Mirjana G
AU  - Ivanic MG
AD  - Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, 
      Florida.
AD  - Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee.
AD  - Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona.
AD  - Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, 
      California.
FAU - Jafri, Zainab A
AU  - Jafri ZA
AD  - Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, 
      Florida.
AD  - Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee.
AD  - Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona.
AD  - Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, 
      California.
FAU - Wu, Jashin J
AU  - Wu JJ
AD  - Dr. Walia is with Lake Erie College of Osteopathic Medicine in Bradenton, 
      Florida.
AD  - Dr. Ivanic is with Meharry Medical College in Nashville, Tennessee.
AD  - Dr. Jafri is with Arizona College of Osteopathic Medicin in Glendale, Arizona.
AD  - Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, 
      California.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Aesthet Dermatol
JT  - The Journal of clinical and aesthetic dermatology
JID - 101518173
PMC - PMC8794491
OTO - NOTNLM
OT  - COVID-19
OT  - Chronic idiopathic urticaria
OT  - immunomodulator
OT  - omalizumab
OT  - urticaria
COIS- DISCLOSURES: The author reports no conflicts of interest relevant to the content 
      of this article.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2021/12/01
CRDT- 2022/01/31 05:58
PHST- 2022/01/31 05:58 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
PST - ppublish
SO  - J Clin Aesthet Dermatol. 2021 Dec;14(12):64-65.